Medicare Advantage reimbursement for cardiovascular biomarker testing (CMS 1500 / UB04)
Defines UnitedHealthcare Medicare Advantage reimbursement stances and coding guidance for various cardiovascular disease biomarker tests (Apo B, Lp(a), CRP, homocysteine, novel biomarkers, and multi-biomarker panels) when billed on CMS 1500 or UB04 forms; applies to providers submitting claims to UnitedHealthcare Medicare Advantage.
Policy language and code update in Reimbursement Guidelines section.
New Policy established.
Policy published.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.